CL 232468

RN given refers to parent cpd; structure given in first source

Also Known As:

1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy-9,10-anthraquinone; 1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy-9,10-anthraquinone dihydrochloride; AEAD; CL 232,468; CL-232468

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ambassa, Armelle Rosalie Mbang: 1 article (09/2017)
2.	Dzeufiet, Paul Desire Djomeni: 1 article (09/2017)
3.	Kouamou, Arielle Larissa Ndieudieu: 1 article (09/2017)
4.	Menanga, Joseph Renaud: 1 article (09/2017)
5.	Taiwe, Germain Sotoing: 1 article (09/2017)
6.	Tchoya, Thierry Bang: 1 article (09/2017)

Related Diseases

1.	Left Ventricular Dysfunction 01/01/2023 - "After multivariate analysis, the independent factors of LV dysfunction were wider QRS duration (QRSd) of the VA (odds ratio [OR] 1.02; 95% confidence interval [CI]: 1.00-1.04; p = .046) and the absolute earliest activation time discrepancy (AEAD) between epicardium and endocardium (OR 1.05; 95% CI: 1.00-1.09; p = .048). "
2.	Seizures (Absence Seizure) 09/26/2017 - "AEAD also protected 100% of mice against pentylenetetrazole-induced seizures. "
3.	Infections 10/01/1988 - "In contrast, treatment with the highly substituted anthracenedione AEAD, which has been demonstrated to selectively inactivate T-cytotoxic cells, had no appreciable effect on the kinetics of infection. "

Related Drugs and Biologics

1.	Pentylenetetrazole (Metrazol)
2.	Anthraquinones